IL-6 is considered to be the driving signal of many inflammatory and lymphoproliferative diseases, such as rheumatoid arthritis and Castleman's disease, and several therapies have been developed to target IL-6 signaling pathway (Garbers et al., 2018). This evidence concerns the gene IL6 and rheumatoid arthritis.